查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1559716

腎上腺素自動注射器的全球市場

Epinephrine Autoinjectors
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球腎上腺素自動注射器市場將達到 36 億美元

預計2023年全球腎上腺素自動注射器市場規模為25億美元，預計到2030年將達36億美元，2023年至2030年複合年成長率為4.8%。 0.15克腎上腺素自動注射器是本報告分析的細分市場之一，預計複合年成長率為4.6%，到分析期結束時將達到25億美元。預計未來八年 0.30 克劑量腎上腺素自動注射器領域的複合年成長率為 5.6%。

美國市場預估成長7.561億美元，中國複合年成長率為4.5%

預計2023年美國腎上腺素自動注射器市場規模將達7.561億美元。中國作為世界第二大經濟體，預計2030年市場規模將達到6.345億美元，2023年至2030年的分析期間複合年成長率為4.5%。其他值得注意的地域市場包括日本和加拿大，預計 2023 年至 2030 年將分別成長 4.6% 和 3.8%。在歐洲，德國的複合年成長率預計約為 4.1%。

2024 年新報告的特點

  • 完全訪問影響者參與統計數據
  • 免費存取數位檔案和「MarketGlass」研究平台。我們獨特的 MarketGlass 平台以整合和協作的方式匯集了世界各地專家的創造力和市場知識。我們最先進的工具提供世界一流的市場可視性，同時保護參與者的隱私和身分。本報告中提供的數字、統計數據和市場描述是基於該領域專家和影響者共用的經過充分審查的見解。
  • 使用即時資料模擬器工具和客製化報告功能參與互動式調查。
  • 客戶全面連結同儕協作互動平台，實現企業間智慧交流
  • 1 年免費報告更新
  • 競爭覆蓋範圍，包括主要企業的全球市場佔有率
  • 多個地區公司的市場影響分析（強/活躍/利基/次要）
  • 訪問專家/影響者訪談、播客、新聞稿和活動主題演講的 YouTube 影片

2024 年世界經濟有何預期

貨幣緊縮以及由此帶來的利率上升所帶來的地緣政治影響和經濟不穩定，很可能使2024年全球經濟動盪。一些因素將繼續給復甦之路帶來壓力，包括中東的敵對行動和日益頻繁的氣候災害。儘管存在風險，但一些積極因素正在顯現，包括強勁的通貨緊縮徵兆、緩解對頑固通膨的擔憂、供應鏈正常化以及儘管能源成本出現波動但價格仍趨緩。印度和美國等二十一國集團國家的選舉可能會影響資本流動和投資策略。儘管印度作為全球投資目的地的地位日益突出，但在充滿活力的人才和資本生態系統的推動下，美國科技公司將繼續佔據主導地位。儘管該國經濟放緩，但由於國內經濟富有彈性和有利的法規環境，高科技機會（尤其是矽谷）仍然對尋求高成長潛力的投資者俱有吸引力。歐洲持續應對緊縮的貨幣政策和景氣衰退風險，但英國的前景最嚴峻，2024 年景氣衰退的風險最高。中國仍然是通用憑證，其成長預計將受到政府支出和消費者支出改善的支持。動盪的環境可能為投資者和公司帶來機會和挑戰。將波動性視為成長的催化劑，並以敏捷性和策略遠見來制定投資決策，對於生存仍然至關重要。

受訪企業範例（共44家）

  • ALK-Abello A/S
  • Bausch+Lomb UK Ltd-Emerade
  • Teva Pharmaceutical Industries Ltd.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP11840

Global Epinephrine Autoinjectors Market to Reach $3.6 Billion by 2030

The global market for Epinephrine Autoinjectors estimated at US$2.5 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 4.8% over the period 2023-2030. The 0.15 gm Dosage Epinephrine Autoinjectors, one of the segments analyzed in the report, is expected to record 4.6% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the 0.30 gm Dosage Epinephrine Autoinjectors segment is estimated at 5.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $756.1 Million, While China is Forecast to Grow at 4.5% CAGR

The Epinephrine Autoinjectors market in the U.S. is estimated at US$756.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$634.5 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.8% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 44 Featured) -

  • ALK-Abello A/S
  • Bausch + Lomb UK Ltd- Emerade
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Epinephrine Autoinjectors - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Epinephrine Autoinjectors Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Epinephrine Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Epinephrine Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Individuals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for 0.15 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for 0.15 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for 0.15 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for 0.30 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for 0.30 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for 0.30 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for 0.5 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for 0.5 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for 0.5 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • JAPAN
    • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • CHINA
    • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • EUROPE
    • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Epinephrine Autoinjectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Epinephrine Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • FRANCE
    • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • GERMANY
    • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030

IV. COMPETITION